Ligand Pharmaceuticals Statistics
Share Statistics
Ligand Pharmaceuticals has 19.29M
shares outstanding. The number of shares has increased by 7.19%
in one year.
| Shares Outstanding | 19.29M |
| Shares Change (YoY) | 7.19% |
| Shares Change (QoQ) | 1.91% |
| Owned by Institutions (%) | 98.95% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 13,045 |
| FTD / Avg. Volume | 10.43% |
Short Selling Information
The latest short interest is 1.22M, so 6.34% of the outstanding
shares have been sold short.
| Short Interest | 1.22M |
| Short % of Shares Out | 6.34% |
| Short % of Float | 7.68% |
| Short Ratio (days to cover) | 12.27 |
Valuation Ratios
The PE ratio is -486.05 and the forward
PE ratio is 14.94.
Ligand Pharmaceuticals's PEG ratio is
4.53.
| PE Ratio | -486.05 |
| Forward PE | 14.94 |
| PS Ratio | 11.73 |
| Forward PS | 5.6 |
| PB Ratio | 2.36 |
| P/FCF Ratio | 20.58 |
| PEG Ratio | 4.53 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.93,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.93 |
| Quick Ratio | 8.55 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.07 |
| Interest Coverage | -7.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2,457,838.24 |
| Profits Per Employee | $-59,294.12 |
| Employee Count | 68 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.78 |
Taxes
| Income Tax | 6.55M |
| Effective Tax Rate | 260.13% |
Stock Price Statistics
The stock price has increased by 21.37% in the
last 52 weeks. The beta is 0.76, so Ligand Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.76 |
| 52-Week Price Change | 21.37% |
| 50-Day Moving Average | 106.17 |
| 200-Day Moving Average | 109.45 |
| Relative Strength Index (RSI) | 48.47 |
| Average Volume (20 Days) | 125,031 |
Income Statement
In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M
and earned -4.03M
in profits. Earnings per share was -0.22.
| Revenue | 167.13M |
| Gross Profit | 156.06M |
| Operating Income | -22.61M |
| Net Income | -4.03M |
| EBITDA | 42.94M |
| EBIT | 5.55M |
| Earnings Per Share (EPS) | -0.22 |
Full Income StatementBalance Sheet
The company has 72.31M in cash and 7.11M in
debt, giving a net cash position of 65.2M.
| Cash & Cash Equivalents | 72.31M |
| Total Debt | 7.11M |
| Net Cash | 65.2M |
| Retained Earnings | 498.98M |
| Total Assets | 905.43M |
| Working Capital | 250.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 97.05M
and capital expenditures -1.82M, giving a free cash flow of 95.23M.
| Operating Cash Flow | 97.05M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | 95.23M |
| FCF Per Share | 5.21 |
Full Cash Flow StatementMargins
Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.
| Gross Margin | 93.37% |
| Operating Margin | -13.53% |
| Pretax Margin | 1.51% |
| Profit Margin | -2.41% |
| EBITDA Margin | 25.69% |
| EBIT Margin | -13.53% |
| FCF Margin | 56.98% |
